FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
What's Behind the FDA's New Warning?
Who Faces the Highest Risk?
Live Events
What's Changing in the Vaccine Labels?
What's the FDA Doing Next?
FAQs
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a report.These warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the report.ALSO READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business report.ALSO READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update:"Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the report.The label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business report.ALSO READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the report.The agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business report.The FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business report.Yes, the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Belapur to get 500-bed super specialty hosp post CRZ nod
Navi Mumbai: The state govt approved construction of a 500-bed super-specialty hospital in Belapur to be built in phases. The Navi Mumbai Municipal Corporation (NMMC) received directives to commence this significant project, which aims to enhance public healthcare services in Navi Mumbai. NMMC Commissioner Kailas Shinde confirmed obtaining essential permissions, including environment clearance and new development plan approval. The initial phase involves creating a 100-bed facility at a cost of Rs 250 crore. A previous tender process was suspended due to a High Court PIL regarding environment clearance and development plan approval issues. With current govt authorisation, NMMC plans to present the acquired permissions to the court to proceed with the public hospital construction. "The tender validity was extended and opening of the bidding will commence shortly. The govt urged swift construction initiation for public benefit," Shinde stated. "The comprehensive project, valued at Rs 800 crore, encompasses a medical college and super-specialty hospital with 500 beds. Phase one involves establishing a 100-bed super-specialty hospital at Rs 250 crore. Phase two, budgeted at Rs 550 crore, includes medical college construction and hospital expansion from 100 to 500 beds," explained Belapur MLA Manda Mhatre, who communicated with the chief minister for approval. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai The project faced challenges with partial land falling under the Coastal Regulation Zone (CRZ), requiring clearance. Additionally, NMMC's new draft Development Plan (DP) awaited state approval. "We secured both DP approval and CRZ clearance, clearing construction obstacles," confirmed Shinde. A civic official noted that while the plot was previously designated as a playground in the old DP, NMMC's new DP redesignated it for healthcare facilities. Phase one completion is estimated at 3-4 years. Cidco allocated approximately 32,000 square metres at plot 4, sector 15A, adjacent to civic headquarters in Belapur, for the medical college and super-specialty hospital. NMMC paid Rs 88 crore to Cidco for the land. "The development will utilise 22,000 square metres beyond CRZ restrictions, with approval secured. The remaining 10,000 square metres under CRZ remains non-developable," NMMC clarified. "The pandemic highlighted the necessity for public healthcare facilities when Covid patients struggled to access affordable treatment and specialist care," Mhatre noted. Cidco sources indicate the plot's designation in NMMC's draft DP as a park could be modified for healthcare purposes. However, local residents who use the space as a recreational area expressed opposition.
Time of India
4 hours ago
- Time of India
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
Bengaluru: The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently approved CAR-T cell immunotherapies. REMS is required by the FDA to ensure a drug's benefits outweigh its risks by managing serious safety concerns. The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed warnings for cytokine release syndrome and neurological toxicities, and medication guides. The cancer therapies include Bristol-Myers Squibb's Breyanzi and its partnered therapy Abecma with 2seventy bio , Johnson & Johnson's unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead Sciences' unit Kite's Tecartus and Yescarta. Bristol-Myers Squibb and Gilead Sciences did not immediately respond to Reuters' requests for comment. These are gene therapies that are currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma, the health regulator said. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. In January 2024, the FDA asked several drugmakers to add a serious warning on the label of their cancer therapies that use CAR-T technology after reports of T-cell malignancies and adverse events identified since approval. The FDA earlier said the risk of T-cell malignancies including leukemia and lymphoma applies to all therapies in the class and can lead to hospitalization and death.
Time of India
4 hours ago
- Time of India
No COVID-19 case reported in Mumbai on Fri, says BMC; asks public not to lower guard
Mumbai: No COVID-19 case was reported in Mumbai on Friday, the feat achieved for the first time in about two months, the metropolis' civic body said. In a release, the Brihanmumbai Municipal Corporation also said no new or concerning variant of the virus has been detected in the city as per the Whole Genome Sequencing Report . Mumbai recorded six COVID-19 cases between January and April this year, before a surge in May saw the detection of 435 cases, while the figure for June stood at 539, the release informed. As on Friday, there are 62 active COVID-19 cases in the city, though all patients are showing mild symptoms, the civic body pointed out. "The city witnessed a steady decline in weekly COVID-19 cases in June. The first week of the month saw 202 cases, followed by 186 in the second week, 99 in the third, and just 30 cases in the fourth week. The declining trend and zero-case count are highly positive and important indicators for both the public and the health system," it said. However, citizens should not lower their guard, the BMC emphasised. "Patients showing influenza-like illness (ILI), severe acute respiratory infection (SARI), or COVID-like symptoms are advised to immediately consult a municipal clinic, hospital, or their family doctor. Vulnerable groups, including senior citizens and individuals with underlying health conditions such as diabetes, hypertension, cancer, or kidney ailments, must take extra precautions," the release said. Civic authorities also urged the public to continue practicing cough etiquette, wash hands regularly with soap and water, and maintain a healthy lifestyle to help prevent further spread of the virus.
